Vilsbøll T - Search Results

1

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Bahne E, Sun EWL, Young RL, Hansen M, Sonne DP, Hansen JS, Rohde U, Liou AP, Jackson ML, de Fontgalland D, Rabbitt P, Hollington P, Sposato L, Due S, Wattchow DA, Rehfeld JF, Holst JJ, Keating DJ, Vilsbøll T, Knop FK. Bahne E, et al. Among authors: vilsboll t. JCI Insight. 2018 Dec 6;3(23):e93936. doi: 10.1172/jci.insight.93936. JCI Insight. 2018. PMID: 30518693 Free PMC article. Clinical Trial.

2

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Vilsbøll T, et al. Diabetes Care. 2000 Jun;23(6):807-12. doi: 10.2337/diacare.23.6.807. Diabetes Care. 2000. PMID: 10841001

3

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Vilsbøll T, et al. Diabetes. 2001 Mar;50(3):609-13. doi: 10.2337/diabetes.50.3.609. Diabetes. 2001. PMID: 11246881

4

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Diabet Med. 2001 Feb;18(2):144-9. doi: 10.1046/j.1464-5491.2001.00424.x. Diabet Med. 2001. PMID: 11251679

5

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Diabetologia. 2002 Aug;45(8):1111-9. doi: 10.1007/s00125-002-0878-6. Epub 2002 Jul 4. Diabetologia. 2002. PMID: 12189441

6

Vilsbøll T, Agersø H, Krarup T, Holst JJ. Vilsbøll T, et al. J Clin Endocrinol Metab. 2003 Jan;88(1):220-4. doi: 10.1210/jc.2002-021053. J Clin Endocrinol Metab. 2003. PMID: 12519856

7

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. Vilsbøll T, et al. J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13. doi: 10.1210/jc.2002-021873. J Clin Endocrinol Metab. 2003. PMID: 12788877

8

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Regul Pept. 2003 Jul 15;114(2-3):115-21. doi: 10.1016/s0167-0115(03)00111-3. Regul Pept. 2003. PMID: 12832099

9

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Among authors: vilsboll t. Diabetes Care. 2003 Sep;26(9):2581-7. doi: 10.2337/diacare.26.9.2581. Diabetes Care. 2003. PMID: 12941722 Clinical Trial.

10

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ. Vilsbøll T, et al. J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903. doi: 10.1210/jc.2003-030738. J Clin Endocrinol Metab. 2003. PMID: 14557471 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

445 results

Search Page

Filters